You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-…

Article metrics

Article menu

Download PDFPDF

Oral Presentations
FRIDAY, 14 JUNE 2019
Osteoarthritis: Research in motion
How to treat SpA? From physiotherapy to new IL-17 blocking drugs
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
Free

 

Online download statistics by month:

Online download statistics by month: May 2019 to August 2023

AbstractFullPdf
May 2019202
Jun 2019144043
Jul 2019690172
Aug 20193809
Sep 20193809
Oct 201963020
Nov 20193809
Dec 20194906
Jan 20203508
Feb 20203902
Mar 202059010
Apr 20203903
May 20204605
Jun 20203205
Jul 20202105
Aug 20203002
Sep 20204909
Oct 202044011
Nov 20202109
Dec 20201604
Jan 20211104
Feb 2021404
Mar 20211705
Apr 2021801
May 2021007
Jun 2021102
Jul 2021204
Aug 2021003
Sep 2021103
Oct 202118020
Nov 202123013
Dec 20211201
Jan 20221301
Feb 20221800
Mar 2022602
Apr 20221603
May 20221608
Jun 20222906
Jul 20221503
Aug 20221603
Sep 20221804
Oct 20223204
Nov 20222006
Dec 20221403
Jan 20231906
Feb 20231200
Mar 20231401
Apr 2023607
May 2023601
Jun 20231803
Jul 2023605
Aug 2023501
Total12680477